JQ1

CI-DRUG-00000320Explore in graph →CHEMBL1957266 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (9)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–9 of 9 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRD4 Overexpression2
JQ1	Childhood Medulloblastoma

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

MYCL EXPRESSION1
I-BET151 + JQ1Substitutes	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	1	accepted	EID1706 Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strong… (full text at CIViC) PMID 27276402 · Suzuki et al., 2016 · Open in CIViC	civic

MYCN Amplification2
JQ1	Neuroblastoma	Predictive	D	Supports Sensitivity Response	4	submitted	EID6017 Integration of genetic features with chemosensitivity data revealed a correlation between MYCN amplification and sensitivity to bromodomain inhibition. BET inhibition conferred a significant survival … (full text at CIViC) PMID 23430699 · Puissant et al., 2013 · Open in CIViC	civic
JQ1 + PanobinostatCombination	Neuroblastoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID6019 JQ1 and panobinostat synergistically reduced LIN28B gene and N-Myc protein expression, and synergistically induced growth inhibition and apoptosis in neuroblastoma cells, but not normal nonmalignant c… (full text at CIViC) PMID 26733615 · Shahbazi et al., 2016 · Open in CIViC	civic

MEN1 Loss-of-function1
JQ1	Neuroendocrine Tumor	Predictive	D	Supports Sensitivity Response	2	submitted	EID9249 Neuroendocrine tumors (NETs) of the pancreas (PNETs) and bronchus (BNETs) have mutations of the multiple endocrine neoplasia type 1 (MEN1) gene, which encodes menin that modifies histones by interacti… (full text at CIViC) PMID 28504695 · Lines et al., 2017 · Open in CIViC	civic

NUTM1 Fusion1
JQ1	NUT CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1781 Treatment of the patient-derived 797 NMC cell line for 48 hours with JQ1 (500 nM) provoked terminal differentiation which was accompanied by growth arrest and sustained inhibition of proliferation. … (full text at CIViC) PMID 20871596 · Filippakopoulos et al., 2010 · Open in CIViC	civic

GNA11 Mutation1
JQ1	Uveal Melanoma	Predictive	D	Supports Sensitivity Response	1	accepted	EID1211 Preclinical study in uveal melanoma cell lines. Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild typ… (full text at CIViC) PMID 26397223 · Ambrosini et al., 2015 · Open in CIViC	civic

GNAQ Mutation1
JQ1	Uveal Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID1210 Preclinical study in uveal melanoma cell lines. Cell lines (n=4) with GNAQ mutation (92.1, Omm1.3, Mel270, Mel202) were more sensitive to BRD4 inhibition with JQ1 than GNAQ/GNA11 wild type (n=3) cell … (full text at CIViC) PMID 26397223 · Ambrosini et al., 2015 · Open in CIViC	civic